Comparative guide · 5 min read

Boswellia vs MSM for Joint Pain — what each is actually for

Updated 2026-05-19 · Reviewed by SupplementScore editors · No sponsorships

For knee and hand osteoarthritis, Boswellia serrata (standardised to AKBA, 5-Loxin or Aflapin) has the larger and more consistent trial-level pain-and-function signal. MSM (methylsulfonylmethane) has a smaller but real effect on pain scores, mostly in shorter studies. Both have decent safety records; neither modifies disease progression. In practical terms, Boswellia is the "stronger anti-inflammatory" pick, MSM is the "well-tolerated mild analgesic" pick, and the two stack cleanly when one alone is insufficient.

Quick verdict

ScenarioBetter choiceWhy
Knee osteoarthritis pain, NSAID-avoidingBoswellia (AKBA-standardised)Multiple RCTs show pain/function improvement at 4–12 weeks; effect size larger than MSM.
Hand OA / multi-joint OABoswelliaAnti-inflammatory mechanism more generalisable.
Mild OA wanting low-risk first tryMSMExcellent tolerability profile; effect smaller but cleaner safety story.
Inflammatory arthritis (RA, psoriatic)Neither replaces DMARDsInflammatory arthritis is a rheumatology problem; supplements are at most adjuncts.
Sports-related joint pain / DOMSMSMSmaller signal in resistance-training cohorts; Boswellia data thinner here.
On anticoagulantsMSM (less interaction risk)Boswellia has theoretical antiplatelet potential; MSM has cleaner interaction profile.

How they actually differ

Mechanism — 5-LOX inhibition vs sulphur donor

Boswellia serrata's active boswellic acids — particularly AKBA (acetyl-11-keto-β-boswellic acid) — inhibit 5-lipoxygenase, an enzyme that produces leukotrienes in the inflammatory cascade. This is a different mechanism than NSAID-class COX inhibition, which is why Boswellia can be useful in NSAID-intolerant patients and stacks cleanly with NSAIDs without overlap. Standardised extracts (5-Loxin: 30% AKBA; Aflapin: 20% AKBA in a Boswellia non-volatile oil matrix) have the cleanest trial record.

MSM is a small sulphur-containing molecule (a natural metabolite of DMSO). Its proposed mechanisms include sulphur donation for connective-tissue synthesis, modulation of inflammatory cytokines (TNF-α, IL-6), and antioxidant activity via cysteine support. The effect is broader and shallower than Boswellia's targeted 5-LOX block.

Evidence base by endpoint

Practical rule. For moderate knee or hand OA with bothersome pain, start with an AKBA-standardised Boswellia (Aflapin 100 mg/day or 5-Loxin 250 mg/day) for 8 weeks before judging. If response is partial or you want an additive low-risk layer, add MSM 3 g b.i.d. Both work alongside standard OA care (weight loss, low-impact exercise, physiotherapy); neither replaces it.

Dose and form

Boswellia: standardised extract is the active question. Aflapin 100 mg/day, 5-Loxin 250 mg/day, or generic Boswellia 333 mg t.i.d. of an extract standardised to 65%+ boswellic acids. Take with a fat-containing meal for absorption. Effects typically develop over 4–8 weeks.

MSM: 3 g twice daily is the trial dose for OA. Higher doses (up to 6 g/day) are tolerated; effect is dose-dependent in some trials. Mild GI upset is the most common dose-limiting issue at higher doses.

Safety

Boswellia is well-tolerated. Mild GI upset, occasional skin rash. Theoretical interactions: additive effect with antiplatelet agents (case reports); modulation of CYP3A4 in vitro (clinical relevance uncertain at supplement doses). Discontinue 2 weeks before scheduled surgery for the theoretical antiplatelet concern.

MSM is very well-tolerated. Mild GI upset, occasional headache, sometimes "sulphur burps". No significant drug interactions documented at oral doses. Pregnancy / lactation safety not well studied — typical caution applies.

Cost

Boswellia generic standardised extract runs $0.20–0.50/day. Branded AKBA extracts (5-Loxin, Aflapin) run $0.50–1.00/day. MSM runs $0.15–0.40/day at OA-trial doses.

The OA layer supplements work alongside

What we'd actually buy

For moderate symptomatic knee or hand OA in an NSAID-cautious adult, with rheumatology / GP sign-off: Aflapin 100 mg/day for an 8-week trial, with WOMAC self-tracking. If response is partial, add MSM 3 g b.i.d. and reassess at 12 weeks. If response is inadequate by 12 weeks, escalate — this is what duloxetine, intra-articular interventions, and (where appropriate) joint replacement exist for.

Sources

Read more: